{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:23:45Z","timestamp":1791822225079,"version":"4.3.4"},"reference-count":83,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-breast-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.clbc.2024.09.017","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T19:16:05Z","timestamp":1727550965000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Effective Strategies for the Prevention and Mitigation of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia: Optimizing Patient Care"],"prefix":"10.1016","volume":"25","author":[{"given":"Heather N.","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus D.","family":"Goncalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail M.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica L.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope S.","family":"Rugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Gradishar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan M.","family":"Zylla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Bergenstal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clbc.2024.09.017_bib0001","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/nyas.14572","article-title":"Pancreatic islet reserve in type 1 diabetes","volume":"1495","author":"Flatt","year":"2021","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.clbc.2024.09.017_bib0002","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/461917","article-title":"Hyperglycemia, a neglected factor during cancer progression","volume":"2014","author":"Duan","year":"2014","journal-title":"Biomed Res Int"},{"issue":"4","key":"10.1016\/j.clbc.2024.09.017_bib0003","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.clon.2018.01.003","article-title":"Hyperglycaemia and survival in solid tumours: a systematic review and meta-analysis","volume":"30","author":"Barua","year":"2018","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"4","key":"10.1016\/j.clbc.2024.09.017_bib0004","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jdiacomp.2018.12.012","article-title":"Impact of diabetes and hyperglycemia on health care utilization, infection risk, and survival in patients with cancer receiving glucocorticoids with chemotherapy","volume":"33","author":"Zylla","year":"2019","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.clbc.2024.09.017_bib0005","article-title":"Hyperglycemia and chemoresistance in breast cancer: from cellular mechanisms to treatment response","volume":"11","author":"Qiu","year":"2021","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.clbc.2024.09.017_bib0006","first-page":"565","article-title":"Diabetes management in cancer patients","volume":"30","author":"Flory","year":"2016","journal-title":"Oncology (Williston Park)"},{"issue":"1","key":"10.1016\/j.clbc.2024.09.017_bib0007","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3803\/EnM.2017.32.1.23","article-title":"Acute hyperglycemia associated with anti-cancer medication","volume":"32","author":"Hwangbo","year":"2017","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"2","key":"10.1016\/j.clbc.2024.09.017_bib0008","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10549-020-05618-1","article-title":"Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer","volume":"181","author":"Drullinsky","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.clbc.2024.09.017_bib0009","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","article-title":"The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism","volume":"20","author":"Hoxhaj","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"10.1016\/j.clbc.2024.09.017_bib0010","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(17)30376-5","article-title":"Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"18","author":"Baselga","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2024.09.017_bib0011","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(17)30688-5","article-title":"Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"19","author":"Di Leo","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clbc.2024.09.017_bib0012","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S1470-2045(16)00106-6","article-title":"Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"17","author":"Krop","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clbc.2024.09.017_bib0013","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.annonc.2020.10.596","article-title":"Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial","volume":"32","author":"Dent","year":"2021","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.clbc.2024.09.017_bib0014","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1158\/1078-0432.CCR-16-2888","article-title":"A first-in-human, phase I, dose-escalation study of TAK-117, a selective PI3Kalpha isoform inhibitor, in patients with advanced solid malignancies","volume":"23","author":"Juric","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.clbc.2024.09.017_bib0015","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2174\/156800908786733504","article-title":"The PIK3CA gene as a mutated target for cancer therapy","volume":"8","author":"Gustin","year":"2008","journal-title":"Curr Cancer Drug Targets"},{"issue":"33","key":"10.1016\/j.clbc.2024.09.017_bib0016","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1200\/JCO.2010.34.4879","article-title":"Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer","volume":"29","author":"Miller","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7418","key":"10.1016\/j.clbc.2024.09.017_bib0017","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.clbc.2024.09.017_bib0018","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/bjc.2017.25","article-title":"Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR(+), HER2(-) advanced breast cancer: results from BOLERO-2","volume":"116","author":"Moynahan","year":"2017","journal-title":"Br J Cancer"},{"issue":"13 suppl","key":"10.1016\/j.clbc.2024.09.017_bib0019","article-title":"Clinical significance of PIK3CA and ESR1 mutations in ctDNA and FFPE samples from the MONARCH 2 study of abemaciclib plus fulvestrant","volume":"79","author":"Tolaney","year":"2019","journal-title":"Cancer Res"},{"issue":"13 suppl","key":"10.1016\/j.clbc.2024.09.017_bib0020","article-title":"A systematic literature review of the prevalence of PIK3CA mutations and mutation hotspots in HR+\/HER2- metastatic breast cancer","volume":"78","author":"Mollon","year":"2018","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.clbc.2024.09.017_bib0021","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1002\/jcb.26687","article-title":"The prognostic value of PI3K mutational status in breast cancer: a meta-analysis","volume":"119","author":"Sobhani","year":"2018","journal-title":"J Cell Biochem"},{"issue":"4","key":"10.1016\/j.clbc.2024.09.017_bib0022","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1245\/s10434-007-9751-7","article-title":"PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients","volume":"15","author":"Lai","year":"2008","journal-title":"Ann Surg Oncol"},{"issue":"196","key":"10.1016\/j.clbc.2024.09.017_bib0023","doi-asserted-by":"crossref","first-page":"196ra199","DOI":"10.1126\/scitranslmed.3005747","article-title":"mTORC1 inhibition is required for sensitivity to PI3K p110alpha inhibitors in PIK3CA-mutant breast cancer","volume":"5","author":"Elkabets","year":"2013","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.clbc.2024.09.017_bib0024","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1158\/2159-8290.CD-23-0396","article-title":"STX-478, a mutant-selective, allosteric PI3Ka inhibitor spares metabolic dysfunction and improves therapeutic response in PI3Ka-mutant xenografts","volume":"13","author":"Buckbinder","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clbc.2024.09.017_bib0025","author":"Piqray [prescribing information]","year":"2024"},{"key":"10.1016\/j.clbc.2024.09.017_bib0026","author":"Piqray (alpelisib) [summary of product characteristics]","year":"2020"},{"issue":"20","key":"10.1016\/j.clbc.2024.09.017_bib0027","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2024.09.017_bib0028","unstructured":"U.S. Food & Drug Administration. FDA approves first PI3K inhibitor for breast cancer. 2019; https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-pi3k-inhibitor-breast-cancer. Accessed February 13, 2024."},{"issue":"2","key":"10.1016\/j.clbc.2024.09.017_bib0029","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.annonc.2020.11.011","article-title":"Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1","volume":"32","author":"Andr\u00e9","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2024.09.017_bib0030","series-title":"Presented at: 2023 ASCO Annual Meeting; June 2-6","article-title":"Alpelisib + endocrine therapy in patients with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: analysis of all 3 cohorts of the BYLieve study","author":"Chia","year":"2023"},{"key":"10.1016\/j.clbc.2024.09.017_bib0031","author":"Afinitor [prescribing information]","year":"2022"},{"key":"10.1016\/j.clbc.2024.09.017_bib0032","unstructured":"U.S. Food & Drug Administration. FDA approves capivasertib with fulvestrant for breast cancer. 2023; https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-capivasertib-fulvestrant-breast-cancer. Accessed February 01, 2024."},{"issue":"10","key":"10.1016\/j.clbc.2024.09.017_bib0033","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","article-title":"Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis","volume":"30","author":"Yardley","year":"2013","journal-title":"Adv Ther"},{"issue":"22","key":"10.1016\/j.clbc.2024.09.017_bib0034","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.clbc.2024.09.017_bib0035","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1056\/NEJMra1704560","article-title":"Phosphatidylinositol 3-kinase, growth disorders, and cancer","volume":"379","author":"Goncalves","year":"2018","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.clbc.2024.09.017_bib0036","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1002\/cncr.34928","article-title":"Incidence, risk factors, and management of alpelisib-associated hyperglycemia in metastatic breast cancer","volume":"124","author":"Shen","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2024.09.017_bib0037","doi-asserted-by":"crossref","DOI":"10.1177\/15347354211073163","article-title":"Management of phosphatidylinositol-3-kinase inhibitor-associated hyperglycemia","volume":"21","author":"Goncalves","year":"2022","journal-title":"Integr Cancer Ther"},{"issue":"3","key":"10.1016\/j.clbc.2024.09.017_bib0038","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.cmet.2010.02.002","article-title":"Specific roles of the p110alpha isoform of phosphatidylinsositol 3-kinase in hepatic insulin signaling and metabolic regulation","volume":"11","author":"Sopasakis","year":"2010","journal-title":"Cell Metab"},{"issue":"20","key":"10.1016\/j.clbc.2024.09.017_bib0039","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1056\/NEJMc2302935","article-title":"Alpelisib in intractable non-islet-cell tumor hypoglycemia","volume":"388","author":"Cahn","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clbc.2024.09.017_bib0040","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3390\/cancers15030703","article-title":"Current state and future challenges for PI3K inhibitors in cancer therapy","volume":"15","author":"Sirico","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clbc.2024.09.017_bib0041","series-title":"Presented at: 2023 SABCS Annual Meeting; December 5-9","article-title":"Inavasolib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutated, HR+, HER2- locally advanced or metastatic breast cancer: Phase III INAVO120 primary analysis","author":"Jhaveri","year":"2023"},{"key":"10.1016\/j.clbc.2024.09.017_bib0042","unstructured":"Genentech. FDA grants breakthrough therapy designation to Genentech's inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation. 2024; https:\/\/www.gene.com\/media\/press-releases\/15025\/2024-05-20\/fda-grants-breakthrough-therapy-designat. Accessed September 4, 2024."},{"key":"10.1016\/j.clbc.2024.09.017_bib0043","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. Accessed February 13, 2024. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf."},{"issue":"16_suppl","key":"10.1016\/j.clbc.2024.09.017_bib0044","volume":"40","author":"Bedard","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clbc.2024.09.017_bib0045","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(21)00034-6","article-title":"Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study","volume":"22","author":"Rugo","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4 suppl","key":"10.1016\/j.clbc.2024.09.017_bib0046","volume":"81","author":"Rugo","year":"2021","journal-title":"Cancer Res"},{"issue":"4 suppl","key":"10.1016\/j.clbc.2024.09.017_bib0047","article-title":"Alpelisib + fulvestrant in patients with PIK3CA-mutated, HR+, HER2- advanced breast cancer (ABC) who received chemotherapy or endocrine therapy (ET) as immediate prior treatment: BYLieve Cohort C primary results and exploratory biomarker analyses","volume":"82","author":"Rugo","year":"2022","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.clbc.2024.09.017_bib0048","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.annonc.2020.05.001","article-title":"Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer","volume":"31","author":"Rugo","year":"2020","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.clbc.2024.09.017_bib0049","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10549-021-06476-1","article-title":"Factors leading to alpelisib discontinuation in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative breast cancer","volume":"192","author":"Cheung","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"10.1016\/j.clbc.2024.09.017_bib0050","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/cam4.4579","article-title":"Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment","volume":"11","author":"Liu","year":"2022","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.clbc.2024.09.017_bib0051","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41523-024-00613-x","article-title":"Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique","volume":"10","author":"Gallagher","year":"2024","journal-title":"NPJ Breast Cancer"},{"issue":"7","key":"10.1016\/j.clbc.2024.09.017_bib0052","doi-asserted-by":"crossref","first-page":"e488","DOI":"10.1093\/oncolo\/oyad024","article-title":"Predicting hyperglycemia among patients receiving alpelisib plus fulvestrant for metastatic breast cancer","volume":"28","author":"Ge","year":"2023","journal-title":"Oncologist"},{"issue":"suppl 2","key":"10.1016\/j.clbc.2024.09.017_bib0053","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/j.annonc.2021.03.110","article-title":"A risk analysis of alpelisib (ALP)-induced hyperglycemia using baseline factors in patients with advanced solid tumours and breast cancer: a pooled analysis of X2101 and SOLAR-1","volume":"32","author":"Rodon","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2024.09.017_bib0054","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.breast.2021.12.016","article-title":"A multidisciplinary approach to optimizing care of patients treated with alpelisib","volume":"61","author":"Rugo","year":"2022","journal-title":"Breast"},{"issue":"7","key":"10.1016\/j.clbc.2024.09.017_bib0055","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.3390\/cancers14071598","article-title":"Management strategies for hyperglycemia associated with the alpha-selective PI3K inhibitor alpelisib for the treatment of breast cancer","volume":"14","author":"Tankova","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"5 suppl","key":"10.1016\/j.clbc.2024.09.017_bib0056","article-title":"Metformin (MET) for the prevention of alpelisib (ALP)-related hyperglycemia (HG) in PIK3CA-mutated, hormone receptor-positive (HR[+]) HER2-negative (HER2[-]) advanced breast cancer (ABC): the METALLICA study","volume":"83","author":"Borrego","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2024.09.017_bib0057","unstructured":"Centers for Disease Control and Prevention. National Diabetes Statistics Report website. Accessed February 13, 2024. https:\/\/www.cdc.gov\/diabetes\/data\/statistics-report\/index.html."},{"key":"10.1016\/j.clbc.2024.09.017_bib0058","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10549-024-07405-8","article-title":"SGLT2 inhibition improves PI3Kalpha inhibitor-induced hyperglycemia: findings from preclinical animal models and from patients in the BYLieve and SOLAR-1 trials","volume":"208","author":"Borrego","year":"2024","journal-title":"Breast Cancer Res Treat"},{"issue":"16_suppl","key":"10.1016\/j.clbc.2024.09.017_bib0059","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.e13041","article-title":"Treatment of alpelisib induced hyperglycemia with sodium-glucose cotransporter-2 inhibitors: a single institution experience","volume":"40","author":"Brugioni","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2024.09.017_bib0060","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10549-023-07110-y","article-title":"Sodium-glucose cotransporter-2 inhibitors for hyperglycemia in phosphoinositide 3-kinase pathway inhibition","volume":"203","author":"Weintraub","year":"2023","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl 1","key":"10.1016\/j.clbc.2024.09.017_bib0061","first-page":"S1","article-title":"Standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"issue":"7719","key":"10.1016\/j.clbc.2024.09.017_bib0062","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41586-018-0343-4","article-title":"Suppression of insulin feedback enhances the efficacy of PI3K inhibitors","volume":"560","author":"Hopkins","year":"2018","journal-title":"Nature"},{"issue":"10 Pt A","key":"10.1016\/j.clbc.2024.09.017_bib0063","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1016\/j.bbadis.2015.07.009","article-title":"Adaptive changes in amino acid metabolism permit normal longevity in mice consuming a low-carbohydrate ketogenic diet","volume":"1852","author":"Douris","year":"2015","journal-title":"Biochim Biophys Acta"},{"issue":"11","key":"10.1016\/j.clbc.2024.09.017_bib0064","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41568-018-0061-0","article-title":"Fasting and cancer: molecular mechanisms and clinical application","volume":"18","author":"Nencioni","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.clbc.2024.09.017_bib0065","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cmet.2013.12.008","article-title":"Fasting: molecular mechanisms and clinical applications","volume":"19","author":"Longo","year":"2014","journal-title":"Cell Metab"},{"key":"10.1016\/j.clbc.2024.09.017_bib0066","series-title":"Presented at: 2023 SABCS Annual Meeting; December 5-9","article-title":"An updated analysis of risk factor identification and hyperglycemia prevention with alpelisib + 1fulvestrant in PIK3CA-mutated, HR+, HER2- advanced breast cancer","author":"Moore","year":"2023"},{"issue":"2","key":"10.1016\/j.clbc.2024.09.017_bib0067","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10549-022-06798-8","article-title":"Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer","volume":"197","author":"Burnette","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2024.09.017_bib0068","series-title":"Presented at: San Antonio Breast Cancer Symposium Virtual Meeting; December 6-10","article-title":"Metformin (MET) for the prevention of alpelisib (ALP)-related hyperglycemia (HG) in PIK3CA-mutated, hormone receptor-positive (HR[+])\/HER2\u2013 Negative (HER2[\u2013]) advanced breast cancer (ABC): the METALLICA study","author":"Llombart-Cussac","year":"2022"},{"key":"10.1016\/j.clbc.2024.09.017_bib0069","series-title":"Presented at: American Society of Clinical Oncology Annual Meeting; June 3-7","article-title":"Targeting insulin feedback to enhance alpelisib (TIFA): a phase II randomized trial in metastatic PIK3CA-mutant hormone receptor-positive breast cancer","author":"Shen","year":"2022"},{"key":"10.1016\/j.clbc.2024.09.017_bib0070","unstructured":"Clinicaltrials.gov. Study of safety and efficacy of dapagliflozin + metformin XR versus metformin XR in participants with HR+, HER2-, advanced breast cancer while on treatment with alpelisib and fulvestrant (EPIK-B4) (NCT04899349). Accessed February 12, 2024. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04899349."},{"key":"10.1016\/j.clbc.2024.09.017_bib0071","unstructured":"ClinicalTrials.gov. Alpelisib, fulvestrant and dapagliflozin for the treatment of HR+, HER2-, PIK3CA-mutant metastatic breast cancer (NCT05025735). Accessed February 12, 2024. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05025735."},{"issue":"1","key":"10.1016\/j.clbc.2024.09.017_bib0072","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2174\/1573399811666150701143112","article-title":"HbA1c, fructosamine, and glycated albumin in the detection of dysglycaemic conditions","volume":"12","author":"Ribeiro","year":"2016","journal-title":"Curr Diabetes Rev"},{"issue":"3","key":"10.1016\/j.clbc.2024.09.017_bib0073","doi-asserted-by":"crossref","first-page":"400","DOI":"10.2337\/dc18-1444","article-title":"Validation of time in range as an outcome measure for diabetes clinical trials","volume":"42","author":"Beck","year":"2019","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.clbc.2024.09.017_bib0074","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2337\/dc20-1862","article-title":"Time in range in relation to all-cause and cardiovascular mortality in patients with type 2 diabetes: a prospective cohort study","volume":"44","author":"Lu","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clbc.2024.09.017_bib0075","unstructured":"Clinicaltrials.gov. Utilizing continuous glucose monitoring to characterize and manage hyperglycemia in patients initiating alpelisib (NCT06083038). Accessed February 12, 2024. https:\/\/www.clinicaltrials.gov\/study\/NCT06083038."},{"issue":"12 suppl","key":"10.1016\/j.clbc.2024.09.017_bib0076","article-title":"SGLT2 inhibition improves BYL719-induced hyperglycemia and hyperinsulinemia in rat pre-clinical models","volume":"20","author":"Schnell","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"10.1016\/j.clbc.2024.09.017_bib0077","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1089\/dia.2018.0246","article-title":"Strategy for mitigating DKA risk in patients with type 1 diabetes on adjunctive treatment with SGLT inhibitors: a STICH protocol","volume":"20","author":"Garg","year":"2018","journal-title":"Diabetes Technol Ther"},{"issue":"6","key":"10.1016\/j.clbc.2024.09.017_bib0078","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2337\/dc18-2316","article-title":"International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors","volume":"42","author":"Danne","year":"2019","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.clbc.2024.09.017_bib0079","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1111\/dom.13811","article-title":"Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: the STOP DKA protocol","volume":"21","author":"Goldenberg","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clbc.2024.09.017_bib0080","series-title":"Presented at: American Society of Clinical Oncology 2023 Annual Meeting; June 2-6","article-title":"Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant HR+, HER2- advanced breast cancer: characterization and management of frequent adverse events from the phase III CAPItello-291 trial","author":"Rugo","year":"2023"},{"issue":"7","key":"10.1016\/j.clbc.2024.09.017_bib0081","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S1470-2045(22)00284-4","volume":"23","author":"Howell","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2024.09.017_bib0082","series-title":"Presented at: Virtual American Society of Clinical Oncology 2020 Annual Meeting; May 29-31","author":"Rugo","year":"2020"},{"key":"10.1016\/j.clbc.2024.09.017_bib0083","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Accessed February 1, 2024. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820924002763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820924002763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T02:01:08Z","timestamp":1736301668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820924002763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1526820924002763"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2024.09.017","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effective Strategies for the Prevention and Mitigation of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia: Optimizing Patient Care","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2024.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}